IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4

Journal of Viral Hepatitis

Volumn 20, Issue 1, 2013, Pages 59-64

  Antaki, N ^a   Bibert, S ^b   Kebbewar, K ^a   Asaad, F ^c   Baroudi, O ^d   Alideeb, S ^d   Hadad, M ^e   Abboud, D ^a   Sabah, H ^d   Bochud, P Y ^b   Negro, F ^f  

^a Saint Louis Hospital   (Syrian Arab Republic)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Squelbiye National Hospital   (Syrian Arab Republic)

^d Damascus Hospital   (Syrian Arab Republic)

^e Ibn Nafis Hospital   (Syrian Arab Republic)

^f University Hospitals   (Switzerland)

Author keywords

antiviral therapy; chronic hepatitis C; hepatitis C virus genotypes; IL28B; interferon

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SYRIA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870999143     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01621.x     Document Type: Article

References (16)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
2. Lavanchy D,. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115.
3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 2009; 461: 399-401.
4. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
5. Tanaka Y, Nishida N, Sugiyama M, et al. Genome- wide association of IL28B with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
6. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome- wide association study. Gastroenterology 2010; 138: 1338-1345.
7. Mangia A, Thompson AJ, Santoro R, et al. IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
8. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment- naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
9. De Nicola S, Aghemo A, Rumi MG, et al. An IL28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55: 336-342.
10. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-532.
11. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51: 788-795.
12. Rallón NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus- coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25: 1025-1033.
13. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
14. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-355.
15. Moucari R, Ripault MP, Martinot- Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV- 4. Gut 2009; 58: 1662-1669.
16. Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012; doi: 10.1136/gutjni- 2012- 302019.